Outlook therapeutics® announces uk mhra marketing authorization of lytenava™ (bevacizumab gamma) for the treatment of wet amd

Iselin, n.j., july 08, 2024 (globe newswire) -- outlook therapeutics, inc. (nasdaq: otlk), a biopharmaceutical company focused on development and commercialization of ons-5010/lytenava™ (bevacizumab-vikg; bevacizumab gamma) for the treatment of retina diseases, today announced that the united kingdom (uk) medicines and healthcare products regulatory agency (mhra) has granted marketing authorization for lytenava™ (bevacizumab gamma), an ophthalmic formulation of bevacizumab for the treatment of wet amd in the uk. lytenava™ (bevacizumab gamma) is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet amd in the eu and uk.
AMD Ratings Summary
AMD Quant Ranking